Prospects & Overviews
The two faces of FBW7 in cancer drug resistance
Article first published online: 30 AUG 2011
Copyright © 2011 WILEY Periodicals, Inc.
Volume 33, Issue 11, pages 851–859, November 2011
How to Cite
Wang, Z., Fukushima, H., Gao, D., Inuzuka, H., Wan, L., Lau, A. W., Liu, P. and Wei, W. (2011), The two faces of FBW7 in cancer drug resistance. Bioessays, 33: 851–859. doi: 10.1002/bies.201100101
- Issue published online: 17 OCT 2011
- Article first published online: 30 AUG 2011
- Manuscript Accepted: 1 AUG 2011
- Manuscript Revised: 31 JUL 2011
- Manuscript Received: 10 JUL 2011
- National Institute of General Medicines, NIH. Grant Number: GM089763
- drug resistance;
- tumor suppressor
Chemotherapy is an important therapeutic approach for cancer treatment. However, drug resistance is an obstacle that often impairs the successful use of chemotherapies. Therefore, overcoming drug resistance would lead to better therapeutic outcomes for cancer patients. Recently, studies by our own and other groups have demonstrated that there is an intimate correlation between the loss of the F-box and WD repeat domain-containing 7 (FBW7) tumor suppressor and the incurring drug resistance. While loss of FBW7 sensitizes cancer cells to certain drugs, FBW7-/- cells are more resistant to other types of chemotherapies. FBW7 exerts its tumor suppressor function by promoting the degradation of various oncoproteins that regulate many cellular processes, including cell cycle progression, cellular metabolism, differentiation, and apoptosis. Since loss of the FBW7 tumor suppressor is linked to drug resistance, FBW7 may represent a novel therapeutic target to increase drug sensitivity of cancer cells to conventional chemotherapeutics. This paper thus focuses on the new functional aspects of FBW7 in drug resistance.